Centiva Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Centiva Capital’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,635	Closed	-$80.1K	–	1612
2024 Q3	$80.1K	Buy	+15,635	New	+$68.1K	﹤0.01%	1977
2024 Q2	–	Sell	-60,465	Closed	-$194K	–	2024
2024 Q1	$194K	Buy	+60,465	New	+$234K	﹤0.01%	1491
2023 Q4	–	Sell	-22,579	Closed	-$123K	–	1743
2023 Q3	$123K	Buy	+22,579	New	+$149K	﹤0.01%	1485
2021 Q2	–	Sell	-32,211	Closed	-$1.3M	–	1359
2021 Q1	$1.3M	Buy	32,211 +25,520	+381%	+$1.38M	0.05%	271
2020 Q4	$396K	Buy	+6,691	New	+$345K	0.02%	558

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Centiva Capital's ADPT Position: Q4 2024 in Review

Centiva Capital sold out of Adaptive Biotechnologies (ADPT) in Q4 2024, closing a stake of 15,635 shares — an estimated $80.1K sold.

Centiva Capital first reported a position in ADPT in Q4 2020 and held it in 5 quarters. The position peaked at $1.3M in Q1 2021. 207 funds tracked by Wall St. Rank hold ADPT as of Q4 2024.

Centiva Capital reported no remaining Adaptive Biotechnologies position as of Q4 2024 after selling out during the quarter.
Centiva Capital sold 15,635 Adaptive Biotechnologies shares in Q4 2024, an estimated $80.1K.
Centiva Capital first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 5 quarters.
Centiva Capital's Adaptive Biotechnologies position peaked at $1.3M in Q1 2021.
207 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.